• What are the Long-term Effects of DAA Therapy on HCV-associated Cryoglobulinemia Vasculitis?

What are the Long-term Effects of DAA Therapy on HCV-associated Cryoglobulinemia Vasculitis?

More than 95% of patients with hepatitis C virus–associated cryoglobulinemia vasculitis (HCV-CryoVas) have a full or partial response of symptoms to treatment with direct-acting antiviral (DAA) agents, researchers report in a long-term follow-up study in the February issue of Clinical Gastroenterology and Hepatology. Fewer than 5% of patients stopped therapy

Read more
  • Hepatitis C Drugs Might be Cost Effective but Demand Could Bust the Healthcare Bank

Hepatitis C Drugs Might be Cost Effective but Demand Could Bust the Healthcare Bank

Treating patients with hepatitis C virus (HCV) infection using recently approved direct-acting agents can be cost effective, but will also have substantial effects on healthcare costs, researchers show. Recently approved drugs cure more than 90% of patients with hepatitis C and could make the liver disease rare in the United

Read more

New Ways to Treat HCV Infection After Liver Transplant

New direct-acting agents against hepatitis C virus (HCV) can cure the infection when it recurs in patients with liver transplants. Researchers reported findings from 3 separate studies at the 65th Annual Meeting of the American Association for the Study of Liver Diseases last week in Boston. HCV is the leading

Read more